Brokerages Set Danaher Corporation (NYSE:DHR) Price Target at $228.91

Danaher Corporation (NYSE:DHR) has received an average recommendation of “Moderate Buy” from the twenty-five analysts that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $228.9130.

Several equities analysts recently issued reports on DHR shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Citigroup assumed coverage on Danaher in a report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target for the company. TD Cowen lowered their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Stifel Nicolaus dropped their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, Weiss Ratings upgraded Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th.

Danaher Stock Up 0.3%

Shares of NYSE DHR opened at $219.42 on Friday. The company has a market capitalization of $154.25 billion, a P/E ratio of 38.97, a price-to-earnings-growth ratio of 2.72 and a beta of 0.78. Danaher has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company’s 50 day moving average price is $195.80 and its 200-day moving average price is $192.40.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the firm posted $0.77 EPS. The company’s quarterly revenue was up 5.5% on a year-over-year basis. Equities analysts forecast that Danaher will post 8.53 earnings per share for the current year.

Hedge Funds Weigh In On Danaher

A number of institutional investors and hedge funds have recently modified their holdings of DHR. Studio Investment Management LLC grew its position in shares of Danaher by 3.3% during the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after buying an additional 51 shares during the period. Washington Trust Advisors Inc. lifted its position in shares of Danaher by 453.3% during the 2nd quarter. Washington Trust Advisors Inc. now owns 830 shares of the conglomerate’s stock valued at $158,000 after acquiring an additional 680 shares during the period. Operose Advisors LLC acquired a new position in shares of Danaher during the 2nd quarter valued at $65,000. Saudi Central Bank boosted its stake in Danaher by 90.0% during the second quarter. Saudi Central Bank now owns 44,585 shares of the conglomerate’s stock worth $8,493,000 after acquiring an additional 21,120 shares in the last quarter. Finally, Angeles Wealth Management LLC boosted its stake in Danaher by 29.5% during the second quarter. Angeles Wealth Management LLC now owns 7,237 shares of the conglomerate’s stock worth $1,381,000 after acquiring an additional 1,647 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.